SARS-CoV-2 receptor networks in diabetic and COVID-19 associated kidney disease.

TitleSARS-CoV-2 receptor networks in diabetic and COVID-19 associated kidney disease.
Publication TypeJournal Article
Year of Publication2020
AuthorsMenon, R, Otto, EA, Sealfon, R, Nair, V, Wong, AK, Theesfeld, CL, Chen, X, Wang, Y, Boppanna, A, Luo, J, Yang, Y, Kasson, PM, Schaub, JA, Berthier, CC, Eddy, S, Lienczewski, CC, Godfrey, B, Dagenais, SL, Sohaney, R, Hartman, J, Fermin, D, Subramanian, L, Looker, HC, Harder, JL, Mariani, LH, Hodgin, JB, Sexton, JZ, Wobus, CE, Naik, AS, Nelson, RG, Troyanskaya, OG, Kretzler, M
Date Published2020 Aug 21

<p>COVID-19 morbidity and mortality is increased in patients with diabetes and kidney disease via unknown mechanisms. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) for entry into host cells. Since ACE2 is a susceptibility factor for infection, we investigated how diabetic kidney disease (DKD) and medications alter ACE2 receptor expression in kidneys. Single cell RNA profiling of healthy living donor (LD) and DKD kidney biopsies revealed ACE2 expression primarily in proximal tubular epithelial cells (PTEC). This cell specific localization was confirmed by in situ hybridization. ACE2 expression levels were unaltered by exposures to renin angiotensin aldosterone system inhibitors in DKD. Bayesian integrative analysis of a large compendium of public -omics datasets identified molecular network modules induced in ACE2-expressing PTEC in DKD (searchable at that were linked to viral entry, immune activation, endomembrane reorganization, and RNA processing. The DKD ACE2-positive PTEC module overlapped with expression patterns seen in SARS-CoV-2 infected cells. Similar cellular programs were seen in ACE2-positive PTEC obtained from urine samples of 13 COVID-19 patients who were hospitalized, suggesting a consistent ACE2-coregulated PTEC expression program that may interact with the SARS-CoV-2 infection processes. Thus SARS-CoV-2 receptor networks can seed further research into risk stratification and therapeutic strategies for COVID-19 related kidney damage.</p>

Alternate JournalmedRxiv
PubMed ID32511461
PubMed Central IDPMC7241118
Grant ListR24 DK082841 / DK / NIDDK NIH HHS / United States
U2C DK114886 / DK / NIDDK NIH HHS / United States
UH3 DK114907 / DK / NIDDK NIH HHS / United States